Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review

Paweł Szponar; Piotr Petrasz; Katarzyna Brzeźniakiewicz-Janus; Tomasz Drewa; Piotr Zorga; Jan Adamowicz

doi:10.3389/fonc.2023.1239118

Frontiers in Oncology (Nov 2023)

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review

Paweł Szponar,
Piotr Petrasz,
Katarzyna Brzeźniakiewicz-Janus,
Tomasz Drewa,
Piotr Zorga,
Jan Adamowicz

Affiliations

Paweł Szponar: Department of Urology and Urological Oncology, Multidisciplinary Regional Hospital in, Gorzów Wielkopolski, Poland
Piotr Petrasz: Department of Urology and Urological Oncology, Multidisciplinary Regional Hospital in, Gorzów Wielkopolski, Poland
Katarzyna Brzeźniakiewicz-Janus: Department and Clinic of Hematology, Oncology and Radiotherapy of the University of Zielona Góra, Multidisciplinary Regional Hospital in, Gorzów Wielkopolski, Poland
Tomasz Drewa: General and Oncological Urology Clinic, University Hospital No. 1 Dr. Antoni Jurasz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland
Piotr Zorga: Clinical Department of Nuclear Medicine with a PET/CT Laboratory of the University of Zielona Góra, Multidisciplinary Regional Hospital in, Gorzów Wielkopolski, Poland
Jan Adamowicz: General and Oncological Urology Clinic, University Hospital No. 1 Dr. Antoni Jurasz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland

DOI: https://doi.org/10.3389/fonc.2023.1239118
Journal volume & issue: Vol. 13

Abstract

Read online

IntroductionRadio-ligand targeted therapy is a new and promising concept of treatment Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were approved for usage in treating prostate cancer, among the multiple others tested. We aimed to review and summarize the literature on the therapeutic isotopes specific for PSMA.MethodsWe performed a scoping literature review of PubMed from January 1996 to December 2022.Results98 publications were selected for inclusion in this review. The studies contained in publications allowed to summarize the data on pharmacokinetics, therapeutic effects, side effects and the medical use of 225Ac and 177Lu radionuclides. The review also presents new research directions for specific PSMA radionuclides.ConclusionRadioligand targeted therapy is a new and promising concept where Lu-177-PSMA-617 have promising outcomes in treatment according to standard of care.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords